MWM
NVAX icon

Mascoma Wealth Management’s Novavax NVAX Stock Holding History

Mascoma Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-528
Closed -$5.43K – 620
2022
Q4 		$5.43K Hold
528
– – ﹤0.01% 481
2022
Q3 		$10K Hold
528
– – ﹤0.01% 405
2022
Q2 		$27K Buy
+528
New +$27.4K 0.01% 316

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mascoma Wealth Management's NVAX Position: Q1 2023 in Review

Mascoma Wealth Management sold out of Novavax (NVAX) in Q1 2023, closing a stake of 528 shares — an estimated $5.43K sold.

Mascoma Wealth Management first reported a position in NVAX in Q2 2022 and held it in 3 quarters. The position peaked at $27K in Q2 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • Mascoma Wealth Management reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • Mascoma Wealth Management sold 528 Novavax shares in Q1 2023, an estimated $5.43K.
  • Mascoma Wealth Management first reported a position in Novavax in Q2 2022 and held it in 3 quarters.
  • Mascoma Wealth Management's Novavax position peaked at $27K in Q2 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Mascoma Wealth Management's 13F filing for Q1 2023, filed 1 May 2023.